Johnson & Johnson
JNJ · NYSE
12/29/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.42 | 0.11 | -1.86 | 0.51 |
| FCF Yield | 5.75% | 4.60% | 3.72% | 4.39% |
| EV / EBITDA | 14.48 | 17.35 | 18.36 | 17.53 |
| Quality | ||||
| ROIC | 13.75% | 16.61% | 12.31% | 13.83% |
| Gross Margin | 69.07% | 68.82% | 69.25% | 70.28% |
| Cash Conversion Ratio | 1.73 | 1.71 | 1.18 | 1.12 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.55% | 2.65% | -1.06% | -1.37% |
| Free Cash Flow Growth | 8.74% | 6.19% | -13.02% | -2.13% |
| Safety | ||||
| Net Debt / EBITDA | 0.55 | 0.32 | 1.01 | 0.72 |
| Interest Coverage | 29.34 | 30.32 | 76.13 | 114.44 |
| Efficiency | ||||
| Inventory Turnover | 2.21 | 2.37 | 2.40 | 2.25 |
| Cash Conversion Cycle | 106.12 | 85.04 | 82.81 | 77.58 |